Skip to main content

Table 2 Baseline imaging characteristics

From: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation—data from the prospective IVEPSA study

MRI

 Synovitis (%)

66.7%

  PSAMRIS synovitis (median, IQR)

1 (0, 2)

  PSAMRIS synovitis (mean ± SD)

2.17 ± 4.6

 Osteitis (%)

27.8%

  PSAMRIS osteitis (median, IQR)

0 (0, 0)

  PSAMRIS osteitis (mean ± SD)

0.44 ± 1.89

 Erosion (%)

72.2%

  PSAMRIS erosion (median, IQR)

1 (0, 4)

  PSAMRIS erosion (mean ± SD)

2.56 ± 3.7

 Proliferation (%)

33.3%

  PSAMRIS proliferation (median, IQR)

0 (0, 1)

  PSAMRIS proliferation (mean ± SD)

0.44 ± 0.71

 Periarticular (%)

16.7%

  PSAMRIS periarticular (median, IQR)

0 (0, 0)

  PSAMRIS periarticular (mean ± SD)

0.28 ± 0.67

 Tenosynovitis (%)

55.6%

  PSAMRIS tenosynovitis (median, IQR)

0 (0, 1)

  PSAMRIS tenosynovitis (mean ± SD)

0.61 ± 1.15

 Total PSAMRIS (median, IQR)

4 (0.75, 7.25)

 Total PSAMRIS (mean ± SD)

6.5 ± 8.85

HR-pQCT

 Erosions (%)

58.8%

  Erosion no. (median, IQR)

1 (0, 1.75)

 Enthesiophytes (%)

41.2%

  Grade 1

23.5%

  Grade 2

17.6%

  Grade 3

0%

  1. Data are based on 18 psoriasis patients who completed the study
  2. PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system, MRI magnetic resonance imaging, HR-pQCT high-resolution peripheral quantitative computed tomography, IQR interquartile range, SD standard deviation